Argenx Presents Efgartigimod Data at EULAR 2025 Conference
Argenx, a biotechnology company based in Belgium, has presented new data on its efgartigimod asset at the EULAR 2025 conference. The data highlights positive phase 2 proof-of-concept results in myositis and Sjogren’s disease.
The results demonstrate the potential of efgartigimod in treating these conditions. Efgartigimod is a monoclonal antibody designed to target and neutralize the FcRn receptor, which plays a key role in the pathogenesis of autoimmune diseases.
Key Findings:
- Positive phase 2 proof-of-concept results in myositis and Sjogren’s disease
- Efgartigimod demonstrates potential in treating these conditions
Market Analysis:
The current price of Argenx stock stands at 472.8 EUR.
- 52-week high: 658 EUR
- 52-week low: 352.9 EUR
- The stock has fallen below its 52-week high, indicating a volatile market.
Further analysis is required to determine the long-term potential of Argenx’s efgartigimod asset.